Wednesday 31 August 2016

Spending on Corporate Wellness in APAC to Reach US$7.4 bn by 2024 as MNCs Encourage Fitness among Employees, finds TMR


The corporate wellness market in Asia Pacific is led by a slew of global and local companies, such as Central Corporate Wellness, ComPsych Corporation, Optum, Inc., JLT Australia (Recovre Group), Truworth Wellness, SOL Wellness, Sodexo, ConneXions Asia, and Bupa Wellness Pty Ltd. Transparency Market Research has observed that the number of companies venturing into this avenue has been steadily rising owing to the growing presence of MNCs in several developing countries.


The opportunity in the corporate wellness market in Asia Pacific was pegged at US$3.4 bn in 2015 and is expected to be worth US$7.4 bn by the end of 2024 at a strong CAGR of 9.0%. Geographical expansions, expansion of product portfolio, mergers and acquisitions, and investing in extensive wellness programs are some of the key growth strategies adopted by the leading players in the Asia Pacific. For instance, in March 2016, Sodexo signed a 10-year contract with Rio Tinto to expand its operations in Australia.

Increase of Non-communicable Diseases Driving Need for Health and Wellness Programs

The prevalence of non-communicable diseases such as diabetes, chronic respiratory diseases, cardiovascular diseases, and cancer has increased significantly in Asia Pacific in recent years. The report has found that these diseases account for at least 8.5 million deaths in Southeast Asia each year. “Employers are, as a result, driven to promote as well as maintain the health and well-being of their employees and offering corporate wellness programs and services has turned out to be the most effective method of doing so,” the lead analyst states. These services not only boost productivity but also reduce overall medical costs.

The corporate wellness market in Asia Pacific is also fueled by government support and initiatives, the rising number of white-collar employees, the willingness of employers to invest in wellness programs, and growing health consciousness among the population.

High Cost of Implementation Restricting Widespread Adoption

“Implementing corporate wellness programs in organizations is a costly affair and companies need to utilize a certain portion of their budget from the revenue generated,” the author of the study comments. Services such as fitness and health risk assessment need high investments and as a result, are cut down by the companies. This restricts the growth of the corporate wellness market.

In addition, the inefficient execution of corporate wellness services is a major restraint to the market and is likely to increase costs for the companies.

China to Lead APAC Corporate Wellness Market throughout Forecast Period

By type of service, the fitness segment led the overall corporate wellness market, accounting for a 38.6% share in 2015, reaching US$2,793.5 mn by 2024. The smoking cessation segment, although the smallest in terms of revenue in 2015, is anticipated to register a strong CAGR of 9.6% during the forecast period. By country, China emerged as the leading revenue generator in 2015 and is projected to retain its position throughout the forecast period. India, on the other hand, is expected to expand at the fastest pace by 2024.

Browse Research Report on Asia Pacific Corporate Wellness Market:
http://www.transparencymarketresearch.com/asia-pacific-corporate-wellness-market.html

Tuesday 30 August 2016

Non-invasive Cancer Diagnostics Market Stimulated by Concerns Regarding Complexities of Invasive Cancer Tests

The significant rise in cancer cases globally and the complexities that are constantly observed with the use of diagnostic methods such as imaging and biopsies have led to an increased demand for non-invasive cancer diagnostic methods in the past few years. Transparency Market Research, in its recent report, titled “Non-Invasive Cancer Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023,” presents a thorough analysis of the market.


The report presents an overview of the key drivers, challenges, and trends that are expected to have a substantial impact on the overall future development of the market over the period between 2015 and 2023. The report also presents a through overview of the regulatory scenario and the competitive landscape of the market.

The rising global prevalence of cancer is the chief factor driving the global non-invasive cancer diagnostics market and is expected to have a vast impact on the market’s future growth prospects as well. The WHO states that by 2020, around 15 mn new cancer cases will be observed every year across the globe, of which ovarian, gastrointestinal, and breast cancer cases will have the highest rate of occurrence. This factor will require diagnostic methods that will enable the early and accurate detection of cancers in their early stage and reduce the considerable amount of burden that cancer treatment can have on national and international economies.

North America is presently the leading contributor to the overall revenues of the global non-invasive cancer diagnostics market, followed by Europe. High awareness about healthcare and disease prevention, and the easy availability of advanced technologies will help the market achieve sustainable growth in these regions in the next few years as well.

However, the market will see the most promising growth in emerging economies across Asia Pacific over the period between 2015 and 2023. The rising prevalence of cancer, increased awareness, and rising affordability of advanced tests will lead to a sizeable rise in demand for a variety of non-invasive cancer tests in the region over the said period.

The global non-invasive cancer diagnostics market features several international firms operating amid intense competition. Rising global investments in research and development of cancer-related diagnostics and treatment methodologies have led to the introduction of several advanced technologies in the market in the past few years. A recent instance is the introduction of Cologuard by Exact Sciences, which was approved by the U.S. FDA for non-invasive diagnosis of colorectal cancer in March 2014.

Some of the key vendors operating in the global non-invasive cancer diagnostics market are Affymetrix Inc, Compugen, Quidel, Abbott Molecular, Immunicon Corporation, Roche Diagnostics, Digene Corporation, Precision Therapeutics, GE Healthcare, and DiagnoCure.

Browse Research Report on Global Non-Invasive Cancer Diagnostics Market:
http://www.transparencymarketresearch.com/noninvasive-cancer-diagnostics-market.html

Monday 29 August 2016

Weight Loss Services Industry Growth and Region-wise Outlook from 2016 to 2023

Weight Loss Services Market: Overview
Overweight and obesity refer to excess body fat and it is related with increased weight-for-height. According to the World Health Organization (WHO) estimates more than 1.4 billion adults 20 years or older are overweight and obese. Obesity not only leads to loss of confidence among obese people, but is also a great concern from health standpoint. Overweight eventually leads a person to several diseases such as cardiovascular diseases (CVD), type 2 diabetes, strokes and even carry a risk of cancer. Obesity and weight gain has become one of the biggest concerns in the developed countries such as the U.S. owing to increasing adoption of sedentary lifestyle among the youth.

Download Exclusive Global Strategic Business Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11897

Weight Loss Services Market: Trends

The global weight loss services market is poised to grow in the coming years, thanks to increasing awareness among people about their health and well being. The huge consumer base is a key market driver for the growth of global weight loss services market and will continue to remain due to increasing global population, particularly in the Asia Pacific and Rest of the World.

Other prominent market drivers include consumer’s increased weight and rising disposable income among people in the developing countries. However, large number of tall and false claims misleads general public about the effectiveness of particular services. Such unfounded loss claims and misleading endorsements restrain the market growth for genuine products and services.

Weight Loss Services Market: Segmentation

The global weight loss services market can be segmented into four major segments, namely, weight loss food and diet chains, weight management programs, health clubs, and other approaches for weight reduction such as liposuction and bariatric surgery. The market is highly competitive in the developed world with simultaneous presence of several multinational and local players. The food and diet chain segment have been growing in incessantly even during the recession period and accounted for largest share in the global weight loss services market. NutriSystem, Inc. is one of the major players in this segment and is engaged in provided meal replacement and weight loss supplements.

Weight Loss Services Market: Region-wise Outlook

Geographically, the global weight loss services market can be segmented into four major geographical regions, namely, North America, Europe, Asia Pacific and Rest of the World. Historically, North America and Europe have been the largest play areas for the players in this market. The market for weigh loss services is getting a boost in the U.S. due to coverage provision of screening and counseling for obesity under the Affordable Care Act (ObamaCare).According to the Health & Social Care Information Centre, obesity levels in England have illustrated a sharp increase during the period 1993 to 2011.

The obesity and overweight population continues to grow in the OECD countries as well. A report – ‘Obesity and Economics of Prevention: Fit or Fat’ from OECD presents the scale of obesity epidemic and recommends that nations make policies to prevent the consequences of obesity on the health and economy of the nation. Therefore, the market for weight loss services is expected to grow continuously in the near future. However, as the economies in Asia Pacific are growing at a rapid pace, the changing lifestyle of people in this region is resulting in more people becoming obese. This presents lucrative opportunity for market players in this highly untapped regional market.

Weight Loss Services Market: Key Players

Some of the players in this market include Northcastle Partners, NutriSystem, Inc., Weight Watchers International, Inc., Jenny Craig, Inc., Medifast, Inc., BistroMD, Inc., and Rosemary Conley Diet & Fitness Clubs.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types and applications.

Browse Research Report on Global Weight Loss Services Market:
http://www.transparencymarketresearch.com/weight-loss-services-market.html

Friday 26 August 2016

Angioplasty Balloons Market at approximately US$1.7 bn and by 2023

A recent report, titled “Angioplasty Balloons Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023”, from Transparency Market Research (TMR) offers the latest insights into the angioplasty balloons market.The report states that the global angioplasty balloons market will progress at a CAGR of 3.50% during the forecast period from 2015 to 2023. In 2014, the global angioplasty balloons market was estimated at approximately US$1.7 bn and by 2023, it is expected to be worth nearly US$2.5 bn.

Download Exclusive Global Strategic Business Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5627

Broadly, the global angioplasty balloons market is segmented on the basis of material, type, and geography. According to balloon type, the global angioplasty balloons market is divided into scoring balloons, drug-coated balloons, cutting balloons, and normal balloons. In 2014, the normal balloons segment led the global angioplasty balloons market, trailed by the drug-coated balloons segment. The drug-coated balloons segment is projected to witness the fastest growth in the global angioplasty balloons market during the forecast period due to the product’s efficiency and steady rise in the volume of percutaneous interventions worldwide. On the contrary, the cutting balloons segment is projected to witness deceleration during the forecast period due to their limitations in comparison to scoring balloons.

By material, the global angioplasty balloons market is classified into non-compliant balloons and semi-compliant balloons. In 2014, the semi-compliant balloons segment led the global angioplasty balloons market and is projected to continue its dominance during the forecasting horizon. Semi-compliant balloons are made of softer materials, which allows them to retain their shape. This has led to improved crossability and deliverability. Furthermore, their flexibility allows physicians to move the balloon catheter smoothly in small vessels.

On the basis of region, the global angioplasty balloons market is classified into North America, Asia Pacific, Europe, the Middle East and North Africa (MENA), Latin America (LATAM), and Rest of the World (RoW). In 2014, Europe and North America collectively held more than 67% of the global angioplasty balloons market. These two regions are enjoying significant growth due to the steady rise in percutaneous intervention procedural volume and the growing aging population. On the other hand, the Asia Pacific segment is expected to expand the fastest in the global angioplasty balloons market due to its emerging medical tourism sector.

The overall angioplasty balloons market is driven by the rising aging population, increasing obese population, and growing prevalence of coronary artery disease. The steady launch of new products is also having a positive impact on the global angioplasty balloons market. Nevertheless, the global angioplasty balloons market is restrained by the growing penetration of players, which has led to a decline in the average selling price of these products.

The report recommends that players operating in the global angioplasty balloons market should focus on developing improved and technologically advanced angioplasty balloons. Furthermore, investing in the emerging markets in Latin America, Asia Pacific, and Africa will also help companies boost their ROI. The leading companies operating in the global angioplasty balloons market are Abbott Vascular, NATEC Medical Limited, ENDOCOR, Medtronic, Johnson & Johnson, and Cook Medical.

Browse Research Report on Global Angioplasty Balloons Market:
http://www.transparencymarketresearch.com/angioplasty-balloons-market.html

Innovations to Dictate the Future of Companies in the Global Medical Image Analysis Software Market

A new market research report by Transparency Market Research, titled “Medical Image Analysis Software Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023”, is a comprehensive study elaborating on the prime roles of medical image analysis software. Aspects such as the current size of the market and the predicted growth trends in the forecast period from 2015 to 2013 have also been included in this study. In addition, the report also throws light on the chief performing products in the market, along with stating the estimated performance of these products all through the forecast horizon. Furthermore, the top application segments as well as end-use segments have also been presented via this research report in order to provide a detailed study on the market for medical image analysis software.  


According to this research report, the advantages associated with the utilization of medical image analysis software such as easy readability, sharing and storing of images, and rising productivity are boosting the market for medical image analysis software. In addition, factors such as the rising geriatric population resulting in increased diagnostic check-ups and the rising convenience owing to image availability on mobile devices are also amongst the chief factors fuelling the market, as per this study. On the other hand, factors such as the issues of data security and the soaring costs of software may have a negative effect on the growth of the market.

On the basis of imaging modality, the report segments the market into magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT) and positron emission tomography (PET), x-ray, computed tomography (CT), microscopy, and ultrasound. In terms of end use, the market for medical image analysis software is segmented into diagnostic centers and general hospitals. 

The report, on the basis of geography, segments the market into Europe, Asia Pacific, North America, and Rest of the World (RoW). Amongst these, North America leads the market and is trailed by Europe. This is owing to the swift technological advancements and the increasing demand for n-dimensional and platform-independent image processing and visualization in these two regions. On the other hand, as per the report, Asia Pacific emerged as the most lucrative medical image analysis software market and is poised to grow at a rapid rate in the coming years. This is owing to the rising occurrence of diseases requiring diagnostic tools, enhancement in health care facilities, and increasing government initiatives in this region.

Carestream Health, Toshiba Medical Systems Corporation, Bruker Corporation, and Merge Healthcare, among others, are the major players operating in the market, as per this study.

Browse Research Report on Global Medical Image Analysis Software Market:
http://www.transparencymarketresearch.com/medical-image-analysis-software-market.html

Thursday 25 August 2016

ADHD Therapeutics Market Witnessing Admirable Growth owing to Persistent Research Efforts

Attention deficit hyperactivity disorder (ADHD), also referred as Attention Deficit Disorder (ADD) or Hyperkinetic Disorder (HKD) is the most common psychiatric disorder among adolescents and children. The disorder is characterized by the presence of inappropriate levels of attention, impulsivity and hyperactivity, commencing in childhood and leading to impairment. Although these symptoms tend to cluster together, some people are majorly hyperactive and impulsive, while others are inattentive. ADHD was for long considered a childhood disorder but there is growing awareness that ADHD is also a significant source of impairment for many adults. The pathophysiology of ADHD is not clearly understood. Majority of scientific research states that ADHD is neurologically based but some experts claim that psychological factors are the major and primary cause of the disorder.

Download Complete Healthcare Analytical Brochure: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=6547

The available medications help to control the symptoms of ADHD but do not cure the disorder. However, medications assist a child to pay attention and complete their school tasks. It is still not clear whether medications are able to improve learning and academic skills among children. Combination of therapies such as behavioral therapy, medication, practical support and counseling can help children to survive normally with ADHD. According to a Research conducted by the National Institute of Mental Health (NIMH) it has proved that medication gives good results when treatment is repeatedly monitored by the doctor and the dosage is modified according to the child's needs.

Attention deficit hyperactivity disorder (ADHD) is a common disorder among children that continue through adolescence and adulthood. Some of the causes that may lead to ADHD are genetic disorders, environmental factors, brain injuries and food additives. The onset of ADHD starts at the age of 7 years. According to The National Institute of Mental Health (NIMH), around 4.1% of adults in the U.S. are affected by ADHD who are 18 years of age and above in a year. Also around 9.0% of children who are aged between 13 to 18 years in the U.S. are affected by ADHD. Boys have four times more risk than girls.

Geographically, the global ADHD therapeutics market is segmented into four major regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). In terms of geography, North America accounts for the highest market in terms of revenue, followed by Europe due to highly developed healthcare industry, high disposable income, ongoing clinical trials, and early approval of drugs in the U.S market. However, Asia Pacific market is also witnessing a very positive growth due to high rate of development in healthcare industry, government initiatives for treatment of mental illness and increasing prevalence of mental disorders.

The global ADHD therapeutics market is witnessing an admirable growth due to the medical advancements, high number of research activities in this segment and high awareness among people about mental illness. However there are many side effects associated with medication such as decreased appetite, sleep problem, headaches, dizziness, Irritability, mood changes and tics. The high cost of treatment and the number of side effects associated with medication are some of the factors that may hinder the growth of ADHD therapeutics market.

Some of the major players operating in ADHD therapeutic market are Amedra Pharmaceuticals LLC, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Noven Therapeutics, LLC, Novartis Pharmaceuticals Corporation and Shire Plc.

Browse Research Report on Global ADHD Therapeutics Market:
http://www.transparencymarketresearch.com/adhd-therapeutics-market.html

Packaging and Labeling (Healthcare) Services Market is expected at a CAGR of 5.3% from 2023

Healthcare packaging calls for well-laid out directives and can be manufactured economically if only a holistic approach is employed. To attain this, medical devices and their packaging need to be developed simultaneously for the optimal use of guidance package that is provided by regulatory bodies for the quality control of these devices. In this context, the device center of the U.S. Food and Drug Administration produces the largest number of guidance documents for medical device manufacturers due to the large variety of medical devices and their specific packaging. 

Download Exclusive Global Strategic Business Report:

The occurrence of industry events also provides guidance for industry players for product development. The PACK EXPO and Pharma EXPO, 2015 held in Las Vegas witnesses a record-breaking industry participation, wherein industry experts provided valuable insights on employing technology for counteracting imitation issues.

At present, the healthcare industry is grappling with the increasing incidence of chronic ailments worldwide. This has necessitated healthcare regulatory bodies to undertake strict quality control of products at every stage right from R&D to production to packaging. On the other hand, pharmaceuticals companies and medical device manufacturers are focused on extending the shelf life of products and need to abide by stringent policies that are in place to counter imitation drug packaging and improper labeling for patient safety. On account of these factors, the global packaging and labeling services market will display a CAGR of 5.3% from 2015 to 2023, says a report by Transparency Market Research.

Q. What lies ahead for the growth of the packaging and labeling services market for healthcare?

A. Though complicated registration and approval processes for the packaging and labeling of pharma products are slowing this market’s growth, this industry is in progression mode due to certain favorable factors. The increasing adoption of nano-enabled packaging will lead to significant growth of this industry. Moreover, increasing adoption of newer packaging techniques in developing countries will open attractive opportunities for the growth of the global packaging and labeling services market for healthcare.

Q. Are pharmaceuticals companies and medical device manufacturers vigilant about their role in public health? 

A. Yes. Firstly, pharma companies adhere to stringent policies that are laid out for the production of pharmaceuticals due to their close association with public well-being. In addition, pharma companies are spending heftily on R&D for advanced packaging techniques to counter issues pertaining to imitation drug packaging. Medical device manufacturers and pharmaceutical companies are also exploring bio-based and green packaging options to minimize the adverse effect of conventional packaging on the environment.  

While a universal packaging technique is not viable for the wide product portfolio of the medical devices and pharmaceuticals industry, industry participants comply with the highest standards of packaging and labeling that are laid out for the same.

Q. How is packaging and labeling services industry for healthcare faring in Europe?

A. Currently, Europe stands as the most lucrative regional market for the packaging and labeling services due to the presence of a large number of pharma and biotech companies. The region held the largest 31.3% of the global market in 2014. Europe is expected to display abundant opportunities for the packaging and labeling services market for healthcare in future as well.

Browse Research Report on Global Packaging and Labeling (Healthcare) Services Market:

Wednesday 24 August 2016

Medical Imaging Equipment Market: Growing Demand for Ultrasound Systems to Expand Market at a CAGR of 5.6% 2015-2023

The players leading the global medical imaging equipment market in 2014 were Philips Healthcare, GE Healthcare, Siemens Healthcare, and CareStream Health, Inc. Collectively, these players held a share of 51% in the overall market in 2014, states Transparency Market Research’s new research report. The report describes the market as highly competitive with only a few players – a scenario that has compounded price wars with each passing year. 

Download Free exclusive Sample of this report:

The report states that the opportunity in the global medical imaging equipment market will be worth US$45.30 bn by 2022 as compared to US$27.70 bn in 2013. Between 2015 and 2023, the market is expected to register a steady CAGR of 5.6%.

“Focusing on reducing equipment prices in line with the budget cuts made by entities in the healthcare sector due to lack of funds will lure in more number of consumers,” says the lead author of this research report. Optimizing replaced devices and equipment by shipping them to regions where the healthcare sector is still struggling could also help companies to expand their geographical reach in the coming years.

Investing in emerging economies of India, Brazil and Russia, where there is a dense population of geriatrics and lack of medical facilities, is expected to open up new channels of earning revenues for the global medical imaging equipment market.

Accuracy in Examining Medical Ailments with 3D Imaging Encourages Investments Medical Imaging Equipment

The growing number of imaging modalities that are bringing in new levels of accuracy with 3D visualization have led to an increasing demand for medical imaging equipment in the recent years. Thus, 3D imaging is extensively being used for breast cancer detection, allowing oncologists to understand the intensity of the disease better. On the other hand, the 2D modalities are gaining momentum in emerging countries such as India and China are investments in healthcare infrastructure are rising.

The high incidence of oral, respiratory, cardiovascular, and orthopedic diseases have also augmented the demand for diagnostic equipment in recent years. A range of chronic diseases have generated a massive demand for imaging modalities such as nuclear imaging equipment, magnetic resonance imaging (MRI), and computed tomography (CT) scanners. A high number of tuberculosis patients in the developing countries have also contributed to the growing adoption of technologically advanced medical imaging equipment in various parts of the world.

High Cost of Scans Dents Consumer Interest

The growing pressure to cut down the healthcare budgets, especially across the U.S., has caused a disruption in the dynamics of the overall medical imaging equipment market. Growing awareness amongst physicians about the health hazards of radiation to the patients and to the equipment handlers is also restraining the overall market. Reluctance of patients to opt for CT scans or MRIs due to their high cost has also hampered the market to a considerable extent.

North America leads Global Market with 4.6% CAGR between 2015 and 2023

X-Ray devices will be the largest product segment in the global market, representing an opportunity worth US$12.34 bn by 2023 as it rises at a CAGR of 4.5% during the forecast period. The revolutionary changes in X-ray technologies and devices will lead the way for this product segment.

TMR expects that North America will retain its dominant position in the global medical imaging equipment market, clocking a steady CAGR of 4.6% between 2015 and 2023. This regional market was valued at US$8.98 bn in 2014 and is expected to reach US$13.50 bn by 2023. Technological advancements, higher adoption rate of medical devices, and supportive healthcare and government infrastructure will also augment the medical imaging equipment market’s growth in North America.

Browse Research Report on Global Medical Imaging Equipment Market:

Human Biobanking Ownership Market Analysis and Industry Overview 2016 to 2024

Transparency Market Research presents a new research report on the global human biobanking ownership market for the 2016-2024 period. The report analyzes demand dynamics and growth opportunities that will influence growth of this market during the aforementioned forecast period. The complete analysis of the development of the global human biobanking ownership market is presented in the report, titled “Human Biobanking Ownership Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024.” 

Download Complete Healthcare Analytical Brochure:

Biobanks play an important role in biomedical research for storing a wide range of biospecimens. These include plasma, blood, saliva, and purified DNA to name a few. Biobanks usually compile specimens based on genetic and other traits such as gender, age, ethnicity, and blood type. 
The genetic data collated by human biobanks is useful for scientists to understand genetic diseases and the impact of environmental and genetic factors on these diseases. The extensive pool of specimens collected in biobanks based on age, gender, education, and lifestyle are crucial for researchers to understand disease indications. These factors are contributing to the growth of the global human biobanking ownership market.

However, the high cost factor of collecting and preserving specimens is inhibiting the growth of this market. Due to the high cost and tedious nature of genome sequencing, government-owned biobanks usually outsource these processes to research organizations. Furthermore, concerns about security of genetic data in human biobanks is also hampering the growth of this market. 

To safeguard genetic information of individuals and to establish rights of gene donors, the global market for human biobanking ownership will be governed by laws in the future. For example, in Estonia, according to the Human Genes Research Act implemented in 1999, donors have full control over who can access their information to safeguard anonymity of individuals in clinical research.  

Asia Pacific is a significant market for human biobanking ownership due to the rapid emergence of private biobanks and clinical research organizations in this region. North America and Europe are also significant markets for human biobanking ownership due to the increasing trend of DNA collection for clinical research in these regions. For example, in Estonia, the national biobank program that commenced in 2000 collected DNA samples of 25% of the country’s population. These DNA samples are not only meant for clinical research, but this data will also be used to develop a robust healthcare system.

Top players that have a significant presence in the global human biobanking ownership market are Affymetrix Inc., Acorda Therapeutics, Autogen Inc., BioCision, BioLife Solutions Inc., Biostorage Technologies Inc., Cesca Therapeutics Inc., Core Dynamics Inc., Abbott Laboratories, Alpha Cord Inc., Biobank Ireland Trust, Biokryo GmbH, Biomatrica Inc., Cells4Life Ltd., China Cord Blood Corporation, and Cryo Bio System.

Browse Research Report on Global Human Biobanking Ownership Market :

Contrast Media Injectors Market expanding at a CAGR of 5.0% from 2020

With a highly consolidated landscape, the global contrast media injectors market is characterized by a high degree of competition between the top three players, namely, Medrad Inc., Bracco Imaging S.p.A, and Mallinckrodt Pharmaceuticals, finds Transparency Market Research (TMR) in a recent report. In 2013, these enterprises collectively held a share of more than 80% of the overall market. Their strong geographical presence and wide-ranging product portfolios have helped these companies in establishing themselves as the leading producers of contrast media injectors across the world. 

View exclusive Global strategic Business report : 

TMR estimates the global market for contrast media injectors, which stood at US$630.1 mn in 2013, to reach an opportunity worth US$886.7 mn by 2020, expanding at a CAGR of 5.0% between 2014 and 2020. New entrants will need to adopt the strategy of product bundling (bundling of their injectors with popular imaging equipment or contrast media) in order to reach out to customers.

Increasing Need for Contrast Scanning to Stimulate Demand for Contrast Media Injectors

“With the growing prevalence of various life-threatening medical conditions, such as cardiac and neurological disorders, there has been a significant increase in diagnostic procedures performed across the world” states an analyst at TMR. According to the Organization for Economic Co-operation and Development (OECD), more than 30,000 scanners and approximately 17,000 MRI platforms were being utilized, globally, in 2013. Over the coming years, these numbers are likely to witness a substantial rise due to the increasing accessibility to these platforms.

Apart from this, the rising incidence of cancer, hemorrhage, complex fractures, cardiovascular disorders, and bone trauma are also projected to increase the need for contrast scanning to identify the tissues that differ in physical density, leading to a surge in the demand for contrast media injectors in the near future.

Currently, developed countries, such as the U.S., the U.K., and Germany provide a wider base for the application of technically advanced imaging platforms. However, in the coming years, emerging economies will present a rather lucrative market for participants due to the augmenting patient pool and the growing need for effective diagnosis.

Demand for Contrast Media Injectors to be Hampered by their High Cost

Although analysts predict the demand for contrast media injectors to rise significantly in the years to come, the high cost associated with them may create some hindrance in their growth trajectory. The cost of contrast media injectors is directly proportional to the level of technological sophistication. As high-end injectors are heavily priced, the availability low-end devices, especially in Asia Pacific, is likely to limit their adoption, resulting in the decline in the overall sale of contrast media injectors in the years to come.

Other than this, the growing concerns regarding adverse reactions, such as mild nausea, vomiting, and rashes, associated with the usage of contrast media or agents are also projected to negatively impact the application of contrast media injectors over the next few years.

North America to Remain Important Market for Contrast Media Injectors

North America has emerged as the key contributor to the revenue generated in this market and is expected to remain in the leading position over the forecast period. In 2013, the region accounted for a total revenue of US$218.3 mn. Asia Pacific, however, is likely to register the fastest growth in the demand for contrast media injectors at a CAGR of 6.50% between 2014 and 2020.

Among applications, the neurology segment led the consumption of contrast media injectors in 2013. However, the cardiology segment is expected to exhibit a higher demand for these injectors that the neurology segment by 2020. CT contrast injectors will remain the most preferred injector across the world throughout the forecast period, states the report.

Browse Research Report on Global Contrast Media Injectors Market :

Tuesday 23 August 2016

Real-Time E-Healthcare System Market Analysis and Industry Trends - 2024

Real-time e-healthcare systems are a digital platform providing instant access to healthcare records to both patients and physicians. They can be accessed by both parties any time and from anywhere. This makes healthcare records much more easily available, making the process of healthcare dispensation more transparent. The elimination of the need for the high-volume paperwork otherwise required throughout the healthcare sector also makes operations in the healthcare sector much more efficient. The growing acknowledgement of these benefits has driven the adoption of real-time e-healthcare systems. 

Download Free exclusive Sample of this report:

Which are the key regional segments of the global real-time e-healthcare market?

The real-time e-healthcare market is driven primarily by the growing demand from the developed world. The early incorporation of e-healthcare solutions in developed countries, with countries such as the U.S. and the U.K starting to adopt electronic healthcare information transmission solutions in the early 21st century, has allowed for easy incorporation of technological advancements in the sector. The smooth implementation of real-time e-healthcare systems has thus helped the market in North America and Europe.

The U.K. NHS is one of the leading adopters of e-healthcare solutions and innovations therein. E-healthcare solutions such as electronic communication channels between hospitals, online referrals, digital imaging facilities, and computerized GP surgeries are already common in the NHS. Earlier this year, the U.K. reiterated its commitment to modernizing the NHS by allocating GBP4 bn (more than US$5 bn) for making the operations of the NHS completely paperless. This funding could be crucial in initiating the use of e-healthcare solutions such as electronic healthcare records and electronic prescriptions, which are vital arms of comprehensive real-time e-healthcare systems. 

The widespread use of smartphones and tablets among the population has also led to the NHS initiating web-based and app-based e-healthcare systems, which could be a massive step towards realizing a nation-wide real-time e-healthcare system. 

What are the notable competitive trends in the real-time e-healthcare systems industry?

Real-time e-healthcare systems have emerged as a highly lucrative field for key players operating in the global real-time e-healthcare systems market. The rising demand for various e-healthcare solutions and the smooth development of communication technologies have made it a question of when rather than if real-time e-healthcare systems get implemented across the world.

Large players in the electronic healthcare industry such as Medtronic, Fitbit, GE Healthcare, Garmin, and Cerner Corporation are likely to utilize mergers and acquisitions to expand their operations in the coming years. The relatively recent emergence of e-healthcare in general and especially real-time e-healthcare systems means that several aspects are still being researched upon, with various startups specializing in particular components. The financial clout of established players can allow them to unite these disparate operations and present a comprehensive real-time e-healthcare solution in the coming years.

Browse Research Report on Global Real-Time E-Healthcare System Market:

Monday 22 August 2016

Growing Number of Pet Owners Create Sizeable Opportunity for Veterinary Antiseptics Market in APAC, Latin America, and Rest of the World, Says TMR

In veterinary medicine, the recent development of multi-resistant bacteria has necessitated the use of alternative therapeutic approaches for bacterial strains that are practically resistant to all oral antibiotics. The topical use of antimicrobial products such as antiseptics has been recognized as the most simple and effective means for the treatment of multi-resistant bacterial infections on the skin surface. Besides this, the use of local antimicrobial products restricts the spread of bacteria, which in turn, reduces the need for broad-spectrum systemic antibiotics. Typically, in veterinary dermatology, the antiseptic treatment is frequently used as a valid alternative to systemic antibiotic therapy due to several clinical advantages.

View exclusive Global strategic Business report : 
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6448

At present, innovations to keep a check on animal health are crucial to feed the growing global population. To address this, governments across the world need to extend their support for animal health as part of the overall human health policy. Particularly in developing countries such as India, lack of skilled veterinarians and inadequate infrastructure for promoting animal health need attention. These factors will result in the Asia Pacific, Latin America, and Rest of the World veterinary antiseptics market to exhibit a CAGR of 5.6% from 2015 to 2023, says Transparency Market Research.

Q. Is the use of antiseptics defined according to their specific need for animals?

A. Yes. The use of antiseptics for animals is clearly defined as per the degree of infection and the body part that is infected. For example, chlorhexidine is well recognized for its use in oral care. Due to its relatively low degree of irritability to tissues, it is generally used as a bactericidal, fungicidal, and virucidal. Chlorhexidine is majorly used among horses, sheep, poultry animals, cats, cows, and dogs for treating abrasions, superficial cuts, and insect stings.

Q. What are the major forces driving the Asia Pacific, Latin America, and Rest of the World veterinary antiseptics market?

A. The growing demand for animal-based food products in emerging markets, which in turn, is accelerating veterinary care and demand for antiseptic products is one of the major factors driving this market. Moreover, the increasing pet ownership in emerging economies is anticipated to augment demand for companion animal antiseptics.

Q. Which is the leading product segment in the Asia Pacific, Latin America, and Rest of the World market for veterinary antiseptics?

A. Iodine and iodophors held the largest market share in 2014. This is because iodine and iodophors are preferred among veterinarians for production as well as companion animal purposes. In addition, iodine and iodophors are increasingly used since they are milder, which makes them suitable for both small and large animals. Iodophors are used as carriers for iodine for providing a sustained and prolonged release of antiseptics.

Q. What inhibits the use of alcohol-based antiseptic in veterinary practices?

A. Though alcohol is primarily used before vaccination or immunization, particularly in small animals such as dogs, cats, and sheep, alcohol causes a higher degree of irritation on tissues and denatured protein. This could help bacteria to breed in open wounds. Low contact time with the skin of alcohol-based antiseptics due to its early vaporization is a major shortcoming of alcohol-based antiseptics.

Browse Research Report on Global Veterinary Antiseptics Market:
http://www.transparencymarketresearch.com/veterinary-antiseptics-market.html

Medical Devices Outsourcing Market to Reach US$40.8 bn by 2018, Increased Demand for Quality Healthcare Drives Growth

The global medical devices outsourcing market is highly fragmented due to the presence of a large number of local and international players, finds a new report by Transparency Market Research. The top four companies that predominantly outsource product manufacturing and services to small and specialized service providers held only 28% of the market in 2011. These are Johnson and Johnson, GE Healthcare, Medtronic, and Baxter International. 


“Business alliances and partnerships are key strategies adopted by top companies for business growth,” says a TMR analyst.

Increased focused on research and development is one of the key growth models that companies receiving outsourced services in the global medical devices outsourcing market are employing for business growth. For instance, the research and development of Creganna-Tactx is focused on developing products with newer component and to develop technologies for minimally and less invasive medical delivery systems.

Need to Reduce Production Cost for Competitive Reasons Fuels Market Growth

A TMR analyst points out, “The ever-increasing demand for quality healthcare is one of the key factors driving the growth of the global medical devices outsourcing market.” At present, the increasing prevalence of chronic diseases is leading to a rising demand for early disease detection for improved disease management. The quality of healthcare delivered depends on the quality of diagnostic devices. This is forcing device manufacturers to outsource product development to specialized third-party product manufacturers to stay ahead in the competitive healthcare industry.

Product outsourcing helps reduce production cost by 10-15% thus allowing companies to survive competition, which is another major factor driving the global medical devices outsourcing market. Today, almost all medical devices are integrated with IT solutions for operational purposes. For example, software for patient monitoring devices that was initially developed in-house is now outsourced to domain experts such as HCL, Persistent Systems, Wipro, and Amdocs.

Outsourcing of product manufacture and services help maximize revenue by means of reducing time-to-market, which is another key factor driving the growth of the global medical devices outsourcing market. This is because a significant amount of time is spent receiving approvals from statutory bodies in the manufacture of medical devices. This time can be reduced by leveraging outsourcing service providers such as Oracle, SAP, Infosys, and Patni that offer process control services for acquiring approvals from statutory bodies. Moreover, the expertise of these providers in developing the relevant application software reduces overall time of production.

Demand for Quality Certifications of Leading Companies Presents Opportunities for Local Service Providers in Asia

“Increasing shift towards quality certifications among Asian service providers and medical device manufacturers is opening growth opportunities for top companies in the global medical devices outsourcing market,” says a TMR analyst. The growing demand for medical devices in the Asian region is attracting top-notch players such as Johnson &Johnson and Boston Scientific to this region. To leverage this, an increasing number of local device manufacturers and service providers are streamlining their processes as per the ISO and requirements of other standardization organizations to attract global players.

The global medical devices outsourcing market is expected to be worth US$40.8 bn by 2018, says TMR. On the basis of application, class II devices account for the largest market share due to moderate risks and minimal regulatory requirements.

Browse Research Report on Global Medical Devices Outsourcing Market:
http://www.transparencymarketresearch.com/medical-devices-outsourcing-market.html

Thursday 18 August 2016

Increased Healthcare Expenditure for Mobility and Well-being in Old Age Boosts Uptake of Implantable Medical Devices Market, states TMR

The U.S. implantable medical devices market features a fair degree of consolidation with a handful of companies enjoying dominance in this market, says the lead author of the study. Some of these companies are Zimmer Holdings, Stryker Corporation, and Abbott Laboratories.

Get a Free Sample Research Report: 

A TMR analyst points out, “Making investments in emerging markets is a primary strategy adopted by key players in the U.S. implantable medical devices market.” An excellent example is Abbott Laboratories. The company is investing heavily in emerging economies to leverage the economic growth that is underway in these nations. Prior to the launch of the product, the company carries out extensive market research for a know-how of the nation’s needs and introduce the ideal product suitable for them.

Business diversification by investing in diversified fields is also what top players in this market are focused on for business growth.

Mergers, acquisitions, and takeovers are one of the key growth models that top players in the U.S. implantable medical devices are focused on for business expansion.

Increasing Incidence of Chronic Diseases Displays Demand for Implantable Devices

“The high incidence of chronic degenerative diseases is one of the primary factors driving the U.S. implantable medical devices market,” points out a TMR analyst. The increasing patient pool of individuals suffering from conditions such as blindness, deafness, orthopedic ailments, and other degenerative diseases can benefit greatly from newer technology-based implantable devices, especially for conditions wherein the pharmacological treatment is ineffective.

An increasing aging population in the U.S. is also exhibiting increased demand for implantable medical devices for age-related ailments. With the baby boomer population getting older, the demand for implantation procedures is on the rise for the treatment of age-related ailments.

Increasing purchasing power parity and growing healthcare expenditure is also augmenting the growth of the U.S. implantable medical devices market.

Implementation of Additional Taxes on Medical Devices Burdens Patients in U.S.

The high price factor of implantable devices, especially the ones that are developed based on high technology, is one of the major factors impeding the growth of the U.S. implantable medical devices market. For instance, the price of cardiac implants escalates with the increasing technical sophistication of the device. Moreover, with the implementation of the Obamacare in 2013, medical devices industry has emerged as one of the highest tax paying sectors in the U.S. This will hike the prices of implantable devices and patients will need to shell out extra money from their pockets for implantation procedures.

The U.S. implantable medical devices market is expected to be worth US$73,944.3 mn by 2018. Orthopedic implants is the leading segment in terms of type of medical implants and is expected to contribute a revenue of US$38,043.3 mn by 2018. On the basis of procedure, orthopedic implantation procedures is the leading segment in the U.S. implantable medical devices market. The increasing incidence of orthopedic procedures and an increasing pool of the elderly is fuelling demand for orthopedic implantation procedures such as spinal fusion and fixation and total keen and hip replacements will increase.

The information presented in the review is based on the Transparency Market Research report, titled “Implantable Medical Devices Market - U.S. Industry Analysis, Size, Share, Trends, Growth And Forecast 2012 - 2018.”

Browse Research Report on Global Implantable Medical Devices Market:

Tuesday 16 August 2016

Saudi Arabia Defibrillators Market: Initiatives Taken by Government and Private Players to Drive Market at 8.3% CAGR during 2014-2020

According to a market research report published by Transparency Market Research, the Saudi Arabia defibrillators market is estimated to expand at a CAGR of 8.3% during the period between 2014 and 2020. The report, titled “Saudi Arabia Defibrillators Market - Industry Analysis, Size, Volume, Growth, Trends and Forecast, 2014 - 2020,” projects the Saudi Arabia defibrillators market to be worth US$49.8 mn by 2020. The overall market stood at a valuation of US$28.6 mn in 2013.


The report points out that the assistance with real time audio and video in local language has enhanced the adoption of automated external defibrillators across public places and office premises. Initiatives taken by government as well as private players will drive the growth of the Saudi Arabia defibrillators market. For example, in 2011, as a measure to offer emergency medical assistance to its onboard customers during sudden cardiac arrest, Gulf Air installed Philips AEDs in all of its aircrafts. The Saudi Arabia Ministry of Health has installed AED units in Mecca for resuscitating pilgrims experiencing sudden cardiac arrest at the Hajj. However, the lack of appropriate awareness campaigns and public-private partnership will impede the sales of the device during the forecast horizon. Further, the lack of local manufacturing in Saudi Arabia increases the overall cost of defibrillators, thereby restricting the growth of the regional market. The overall market has a huge opportunity to grow with the development of defibrillators equipped with inbuilt remote patient monitoring and telemedicine features.

On the basis of product type, the report segments the Saudi Arabia defibrillators market into automated external defibrillators (AED) and advanced life support (ALS) defibrillators. In the last couple of years, increased adoption of AEDs owing to their low cost and user friendly interface has significantly contributed towards the growth of the market. Government agencies and hospitals are organizing several campaigns and training programs to promote awareness about AEDs and ALS defibrillators. ALS defibrillators are usually used in hospital settings due to their efficiency to monitor multiple parameters such as heart rhythm, pulse rate, and oxygen concentration.

In terms of end-users, the report categorizes the Saudi Arabia defibrillators market into public access defibrillators, hospitals, emergency medical services, and business workplaces. Hospitals dominate the overall defibrillators market in Saudi Arabia, followed by emergency medical services and public access defibrillators. Emergency medical services include fire fighters, police vans, and paramedical forces.

Describing the competitive landscape, the report profiles some of the key players in the Saudi Arabia defibrillators market such as Defibtech LLC, Biotronik SE & Co. KG, GE Healthcare, Cardiac Science Corporation, HeartSine Technologies Inc., Nihon Kohden Corporation, Mindray Medical International Ltd., Philips Healthcare, Schiller AG, Physio-Control Inc., and Zoll Medical Corporation. The report provides insightful information about the key players including their financial overview, product portfolio, business strategies, and recent developments.

Browse Research Report on Saudi Arabia Defibrillators Market:
http://www.transparencymarketresearch.com/saudi-arabia-defibrillators-market.html

Sintering Process Market - Global Industry Trends and Forecast 2014 - 2020

A new market study by Transparency Market Research on the global sintering process market presents an in-depth analysis of the said market, with a focus on market trends and opportunities, competitive landscape, and geographical segmentation of the market. The report is titled “Sintering Process Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020.” In this report, the progression of the market in the historic years and in the forecast period  are depicted through an array of graphs and statistical representations of the overall sintering process market.


The report points out that sintering process is exclusively driven due to processes of the powder metallurgy industry. In the coming years, the technology will display a steadfast growth due to its utilization across a host of end-use industries. Sintered metal parts are used in the automotive, electronics, and construction industry among others. However, reasons of environmental deterioration due to sintering are impeding utilization of the process. Nevertheless, many governments around the world are framing regulations that are favorable for the utilization of sintering processes. With consistent technological advancement in sintering technology, the process will be suitable for a host of end-use applications.

Sintering involves applying heat or pressure to solid for solidifying the inner mass without melting into liquid state. For this reasons the temperature that is used in the sintering process is always lower than the melting point of the major constituent of the powder metal. During sintering, the powdered metal is imparted with certain desirable properties, which are otherwise absent in the metal. These include enhancing electrical conductivity, thermal conductivity, strength, and translucency of the powdered metal. Temperature and time, composition of the powdered metal, geometrical structure of powdered particles, density of the powder compact, and composition of atmosphere in the sintering furnace are the parameters that govern a sintering process.

The other attributes that are imparted to the powder metal due to sintering are also discussed in this report. During sintering, the powdered metal particles bond through diffusion, thereby imparting mechanical strength to the porous body. Hence, the reason for sintering to be one of the most widely used industrial techniques for a betterment of capabilities of metals. Ferrous and non-ferrous metals are ideally suitable for sintering; however, rare earth intermetallic, ceramics, and cermet are also suitable for sintering.  

Asia Pacific will display a robust growth in the sintering process industry during the forecast period, says the report. The flourishing automotive and construction industry in the emerging economies if China, Indonesia, and India are reasons for the same. North America and Europe will register a downward growth trend in the sintering industry due to stringent regulations to monitor harmful emissions using sintering.

Browse Research Report on Global Sintering Process Market:
http://www.transparencymarketresearch.com/sintering-process-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Monday 15 August 2016

Implementation of Screening Programs for Diagnosis of Sexually Transmitted Diseases to Promote Uptake of Diagnostic Testing

According to the World Health Organization (WHO), more than 1 mn sexually transmitted infections (STIs) are acquired every day across the globe. Most of them go untreated as a result of lack of diagnosis. Undiagnosed STDs can have critical consequences on maternal, reproductive and newborn health. A large diseased population can challenge the socioeconomic development of a country. Therefore, governments of various countries are encouraging the use of diagnostic testing of STDs to spread awareness amongst the common mass. This is the key factor driving the global diagnostic testing of STDs market. 


According to a study by Transparency Market Research (TMR), the global diagnostic testing of STDs market was valued at US$65.9 bn in 2012 and is anticipated to reach US$108.5 bn by the end of 2019 at a CAGR of 8.10% between 2013 and 2019.

Why are governments taking a keen interest in promoting the growth of the diagnostic testing of STDs market?

Given the huge public health burden that STDs can have, governments across the world have implemented national screening programs that deploy various equipment and machines for the diagnosis of STDs. These programs have encouraged people to undergo diagnosis tests at more affordable costs, thereby increasing the popularity of diagnostic testing of STDs. This has, in turn, boosted the growth of the global diagnostic testing of STDs market.

Another factor that is driving the growth of the global diagnostic testing of STDs is the favorable reimbursement offered by insurers for STDs testing. The coverage provided by health insurance has stimulated the interest of people in undergoing diagnosis test.

Is social stigma besetting the growth of the global diagnostic testing of STDs market?

Those afflicted with STDs commonly tend to shy away from proper testing facilities due to the social stigma associated with the diseases. As a result, a lot less patients actually get diagnosed with STDs in comparison to the number of patients possibly affected by them. This factor is likely to deter the growth of the global diagnostic testing of STDs market.

Other than this, the screening centers are often operated in urban or semi urban areas. This makes these centers out of reach for a large number of STD infected patients who are living in remote locations or rural areas. This, therefore, restrains the growth of the global diagnostic testing of STDs market.
How lucrative is the global diagnostic testing of STDs market for new entrants?

A growing prevalence of STDs has propelled the demand for efficient diagnostics testing of STDs. The presence of large pool of patients along with immense untapped opportunities in regions such as Asia Pacific and MEA is attracting many vendors to cater the market for diagnostic testing of STDs. Moreover, rising awareness for STD diagnosis in developed nations of North America and Europe is fuelling the growth of the global diagnostic testing of STDs market.

However, the stringent regulatory compliance requirements associated with diagnostic testing of STDs are limiting the entry of new vendors. Furthermore, the high investment of capital of research hampers the entry of new players in the global diagnostic testing of STDs market.

Browse Research Report on Global Diagnostic Testing of STDs Market:
http://www.transparencymarketresearch.com/diagnostic-testing-stds.html

Tuesday 9 August 2016

Increased Life Expectancy to Drive the Global Artificial Vital Organs and Medical Bionics Market

The oligopolistic nature of the global artificial vital organs and medical bionics market is mainly characterized by two important factors: The low clinical success rate of artificial organs in the pipeline and the high consolidation activity, reports Transparency Market Research (TMR) in a new study. There is a limited number of players in the artificial vital organs and medical bionics market and each player prefers to operate in a niche segment of the overall market. For instance, the key players in the artificial kidney market are Baxter Healthcare, Gambro AB, Fresenius Medical Care, Nipro Europe, and Asahi Medical. 


“Implementation of high-end technology in new products that are in the pipeline is making them more compatible, durable, and safe, thus resulting in greater life expectancy of the patients, which will escalate the growth of the global artificial vital organs and medical bionics market,” says a TMR analyst. The incorporation of sophisticated technology also indicates the potential new entrants have in this market along with their key products in development.

Growing Prevalence of Organ Failure to Encourage Growth in Demand for Artificial Vital Organs 

During recent times, an increase in the number of cases associated with failure of heart, kidneys, pancreas, and lungs have increased the demand for organ replacements. To put this in perspective, various studies report that the number of patients with acute kidney failure worldwide is increasing at the rate of 7% per year. However, there is a shortage of supply with respect to the demand. The lack of availability of donor organs and bio-artificial organs has substantially increased the need to develop artificial organs.

Organ transplant is not just subjected to availability of organ but also the right match for replacement. “The shortage of suitable organs for transplant has further induced the need for sophisticated artificial organs, which would represent lifesaving technologies as bridge-to-transplant and bridge-to-recovery,” says the TMR analyst. Therefore, an increase in the incidence of organ failure and lack of donor organs is likely to drive the global artificial vital organs and medical bionics market.

Low Cost Effectiveness Detrimental to Use of Artificial Organs and Medical Bionics

Continuous technological advances in artificial organ product designs have made it difficult to redeem clear cost effectiveness. There is a high development cost associated with artificial organ development and medical bionics due to the requirement of substantial resources. The cost effectiveness issue is further intensified by the lack of satisfactory standards and methods.

Artificial organ implantation imposes physiological threats on the patient to make a conscious decision about whether to opt for an artificial organ. It is believed that transplant of an artificial organ may cause disabling injury or even death. It becomes difficult to obtain credibility with respect to artificial organs because of the immense financial, emotional and social strain exerted on caregivers of the transplant patient. All these factors collectively restrain the growth of the artificial organs market.

Artificial Vital Organs to Dominate Owing to Speedy Recovery and Enhanced Outcomes

In 2011, the valuation of the global artificial vital organs and medical bionics market US$17.48 bn and is estimated to reach US$32.32 bn by 2018. By product type, artificial vital organs segment is the leading segment and is expected to retain the same position till 2018. The segment, which was valued at US$15.66 bn in 2015, is anticipated to reach US$19.50 bn by 2018. However, with intensive and rapid technological innovation, medical bionics segment is anticipated to be a faster growing segment.

In terms of geography, North America leads the market and is anticipated to retain its leadership by the end of 2018. The valuation of the regional market is expected to reach US$12.93 bn in 2018. However, Asia Pacific will register highest growth rate owing to the increasing number of new product approvals by regulatory associations.

The information presented in this review is based on a Transparency Market Research report, titled, ‘Artificial Vital Organs and Medical Bionics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 - 2018.’

Browse Research Report on Global Artificial Vital Organs and Medical Bionics Market:
http://www.transparencymarketresearch.com/artificial-vital-organs-medical-bionics.html

Growing Number of Heart Failure Incidences to Augment Demand for Dilated Cardiomyopathy Medications

Dilated cardiomyopathy has led to an increase in heart failures worldwide among adults and children also giving rise to need for heart transplant. Dilated cardiomyopathy can develop between the ages of 20 and 40 years, genetic inheritance being the most common factor affecting 30%-40% of the DCM patients globally. Due to the increasing cases of heart failures, the demand for dilated cardiomyopathy drugs is expected to increase as the need for blockbuster drugs in developed countries is becoming evident. 

According to a report published by Transparency Market Research, the global dilated cardiomyopathy therapeutics market is expected to witness a negative CAGR of -7% from 2014 to 2020. The global dilated cardiomyopathy market was valued at US$651 mn in 2013 and is projected to decrease to US$328.6 mn by 2020. 

Browse Report: 

How can an increase in heart failure cases help drug manufacturers to develop innovative and advanced therapeutics?

According to a study, in every one million children across the globe, six are diagnosed with dilated cardiomyopathy. It is found commonly among children who are under the age of 2 years. There has also been a substantial increase in the number of heart failures among adults as well, leading to a global rise in the demand for dilated cardiomyopathy therapeutics. Of the overall congestive heart failures that occur each year, DCM comprises 30%-40%. Due to this, several leading companies have introduced clinical trials and invested for the development of therapeutics for dilated cardiomyopathy. 

For instance, Cincinnati Children’s Heart Institute announced a breakthrough development on 19 May, 2016 where genetically inherited heart diseases can be diagnosed and treated with the help of biomechanics and stem cells. Similar breakthroughs are underway in the field of dilated cardiomyopathy drugs to help in the growth of the market with better techniques and medications. 

What factors are responsible for the negative growth of the dilated cardiomyopathy therapeutics market?

 DCM drugs segment has no drug that has been approved by FDA till date. The drugs used for the treatment of dilated cardiomyopathy and congestive heart failure are same and have no distinct formulation. DCM drugs are reported to have side effects and this has thus affected revenues from DCM therapeutics substantially. The use of devices and gene therapy that provide enhanced relief without any side effect has highly restrained the dilated cardiomyopathy therapeutics market growth globally.

However, companies in the DCM drug market along with research organizations are working on the approval of aldosterone antagonists combined with ARBs or ACE. It is expected that these drugs will play a positive role in reducing the progress of Duchenne muscular dystrophy. This approval will help in the acceleration of sales of DCM drugs as aldosterone antagonists are one of the main additives in the formulation of DCM medications. 

The increase in genericization activities of DCM drugs will also provide manufacturers with opportunities to improve their product position in the global market and also witness a positive growth of the DCM drugs market.

North America dominated the DCM drugs market in 2013 due to the demand for branded drugs and increasing heart failure cases. Asia Pacific is projected to be the fastest growing market for DCM followed by the Rest of the World owing to the per capita income increase, and improving economic standards in the region. Some of the key players operating in the global DCM drugs market are Celladon Corporation, Novartis International AG, Vericel Corporation, Sanofi S.A., AstraZeneca plc, and GlaxoSmithKilne plc.